Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells.
Bile flow
Cholesterol
Contaminants
Hepatocytes
Liver toxicity
Journal
Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
21
11
2019
accepted:
26
03
2020
pubmed:
8
4
2020
medline:
23
4
2021
entrez:
8
4
2020
Statut:
ppublish
Résumé
Perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) are man-made chemicals that are used for the fabrication of many products with water- and dirt-repellent properties. The toxicological potential of both substances is currently under debate. In a recent Scientific Opinion, the European Food Safety Authority (EFSA) has identified increased serum total cholesterol levels in humans as one major critical effect being associated with exposure to PFOA or PFOS. In animal studies, both substances induced a decrease of serum cholesterol levels, and the underlying molecular mechanism(s) for these opposed effects are unclear so far. In the present study, we examined the impact of PFOA and PFOS on cholesterol homoeostasis in the human HepaRG cell line as a model for human hepatocytes. Cholesterol levels in HepaRG cells were not affected by PFOA or PFOS, but both substances strongly decreased synthesis of a number of bile acids. The expression of numerous genes whose products are involved in synthesis, metabolism and transport of cholesterol and bile acids was strongly affected by PFOA and PFOS at concentrations above 10 µM. Notably, both substances led to a strong decrease of CYP7A1, the key enzyme catalyzing the rate-limiting step in the synthesis of bile acids from cholesterol, both at the protein level and at the level of gene expression. Moreover, both substances led to a dilatation of bile canaliculi that are formed by differentiated HepaRG cells in vitro. Similar morphological changes are known to be induced by cholestatic agents in vivo. Thus, the strong impact of PFOA and PFOS on bile acid synthesis and bile canalicular morphology in our in vitro experiments may allow the notion that both substances have a cholestatic potential that is connected to the observed increased serum cholesterol levels in humans in epidemiological studies.
Identifiants
pubmed: 32253466
doi: 10.1007/s00204-020-02732-3
pii: 10.1007/s00204-020-02732-3
pmc: PMC8241792
doi:
Substances chimiques
Alkanesulfonic Acids
0
Bile Acids and Salts
0
Caprylates
0
Fluorocarbons
0
perfluorooctanoic acid
947VD76D3L
Cholesterol
97C5T2UQ7J
perfluorooctane sulfonic acid
9H2MAI21CL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1673-1686Commentaires et corrections
Type : ErratumIn
Références
EFSA J. 2018 Dec 13;16(12):e05194
pubmed: 32625773
Toxicol Sci. 2013 Nov;136(1):97-106
pubmed: 23945500
Toxicol Lett. 2012 Jul 20;212(2):106-12
pubmed: 22609092
Environ Health Perspect. 2007 Nov;115(11):1596-602
pubmed: 18007991
Int Arch Occup Environ Health. 2007 Nov;81(2):231-46
pubmed: 17605032
Cell Metab. 2015 Aug 4;22(2):228-38
pubmed: 26244932
Gene. 2002 Jan 23;283(1-2):133-43
pubmed: 11867220
Toxicol Sci. 2006 Aug;92(2):476-89
pubmed: 16731579
N Engl J Med. 2003 Jul 31;349(5):474-85
pubmed: 12890847
Toxicol Sci. 2015 May;145(1):157-68
pubmed: 25690737
J Lipid Res. 1998 Nov;39(11):2192-200
pubmed: 9799805
Curr Drug Metab. 2011 Feb;12(2):139-53
pubmed: 21395542
Drug Metab Dispos. 2018 Apr;46(4):387-396
pubmed: 29343608
Crit Rev Toxicol. 2004 Jul-Aug;34(4):351-84
pubmed: 15328768
Toxicol Sci. 2007 Jan;95(1):108-17
pubmed: 17047030
Biochem Biophys Res Commun. 2005 May 6;330(2):395-9
pubmed: 15796896
Drug Metab Dispos. 2012 Jan;40(1):151-8
pubmed: 21994436
Hepatology. 2019 Feb;69(2):666-683
pubmed: 30102412
Toxicology. 2005 Jan 31;206(3):309-23
pubmed: 15588922
Toxicol Lett. 2013 Oct 24;222(2):180-8
pubmed: 23845848
Arch Toxicol. 2018 Jun;92(6):1939-1952
pubmed: 29761207
Ind Health. 2010;48(1):96-107
pubmed: 20160413
Toxicol Appl Pharmacol. 2016 Aug 1;304:18-29
pubmed: 27153767
Toxicol Sci. 2014 Sep;141(1):244-53
pubmed: 24973091
Drug Metab Dispos. 2010 Mar;38(3):516-25
pubmed: 20019244
Hepatology. 2017 Feb;65(2):722-738
pubmed: 27981592
Nat Methods. 2007 Mar;4(3):251-6
pubmed: 17293868
Hepatology. 2013 Apr;57(4):1518-29
pubmed: 23175273
Toxicol In Vitro. 2020 Feb;62:104700
pubmed: 31676336
Ann Transl Med. 2014 Jan;2(1):7
pubmed: 25332983
Gene. 2003 Aug 14;313:71-82
pubmed: 12957378
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Anal Biochem. 2006 Sep 1;356(1):94-9
pubmed: 16750160
Hepatology. 2011 Apr;53(4):1377-87
pubmed: 21480339
Environ Sci Technol. 2011 Oct 1;45(19):8037-45
pubmed: 21469664
Expert Opin Drug Metab Toxicol. 2009 Feb;5(2):137-47
pubmed: 19239393
Toxicol Sci. 2009 Apr;108(2):225-46
pubmed: 19131563
J Lipid Res. 2002 Apr;43(4):533-43
pubmed: 11907135
Eur J Pharm Sci. 2006 May;28(1-2):109-17
pubmed: 16488578
Hepatology. 2003 Mar;37(3):622-31
pubmed: 12601360
Toxicol Sci. 2008 Nov;106(1):162-71
pubmed: 18713766
Adv Pharmacol. 2015;74:263-302
pubmed: 26233910
Toxicol In Vitro. 2013 Sep;27(6):1979-86
pubmed: 23850984
Mol Pharmacol. 1998 Jan;53(1):14-22
pubmed: 9443928
Appl Environ Microbiol. 2012 Aug;78(15):5440-3
pubmed: 22610439
Toxicol Sci. 2015 Oct;147(2):573-87
pubmed: 26198044
Drug Metab Pharmacokinet. 2007 Aug;22(4):287-98
pubmed: 17827783
Sci Rep. 2014 Apr 03;4:4582
pubmed: 24694979
Toxicology. 2012 Mar 11;293(1-3):16-29
pubmed: 22245121
Sci Rep. 2016 May 12;6:24709
pubmed: 27169750
Toxicol Sci. 2007 Oct;99(2):366-94
pubmed: 17519394
J Clin Invest. 2002 Jul;110(1):109-17
pubmed: 12093894